Outcome of Board Meeting held on 14th November 2026, approving the un-audited standalone financial results for the half year ended September 30, 2026, pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The Board Meeting commenced at 04:00 P.M. and concluded at 04:50 P.M. on 14th November 2026.
The financial results include the Statement of Profit and Loss, Balance Sheet, Statement of Cash Flows, and accompanying notes.
Key Quantitative Figures
Balance Sheet (as at 30th September 2026, in ₹ lacs)
Share Capital: ₹1,140.70 (compared to ₹870.70 as at March 31, 2026 and September 30, 2025).
Reserves and Surplus: ₹1,452.85 (compared to ₹554.26 as at March 31, 2026 and ₹299.80 as at September 30, 2025).
Total Equity: ₹2,593.55.
Long-term Borrowings: ₹66.65 (compared to ₹146.32 as at March 31, 2026 and ₹351.47 as at September 30, 2025).
Deferred Tax Liabilities (Net): ₹0.00 (compared to ₹12.11 as at September 30, 2025; not applicable as at March 31, 2026).
Other Long Term Liabilities: ₹22.00 (unchanged from previous periods).
Long-term Provisions: ₹90.38 (compared to ₹82.45 as at March 31, 2026 and ₹68.22 as at September 30, 2025).
Current Liabilities: ₹558.14, including:
Short-term borrowings: ₹0.00 (compared to ₹769.85 as at March 31, 2026 and ₹660.28 as at September 30, 2025).
Trade payables: ₹198.96 (₹98.62 for micro and small enterprises, ₹99.34 for others).
Other current liabilities: ₹146.94.
Short-term provisions: ₹213.24.
Total Liabilities: ₹3,330.72.
Non-current Assets: ₹307.02, including:
Property, Plant and Equipment: ₹254.39.
Intangible Assets: ₹5.60.
Capital Work-in-Progress: ₹2.50.
Deferred Tax Asset (net): ₹42.97.
Long-term loans and advances: ₹1.56.
Current Assets: ₹3,023.71, including:
Inventories: ₹598.43.
Trade receivables: ₹1,853.27.
Cash and cash equivalents: ₹155.52.
Short-term loans and advances: ₹242.73.
Other current assets: ₹173.76.
Total Assets: ₹3,330.72.
Statement of Profit and Loss (for half year ended 30th September 2026, in ₹ lacs)
Revenue from Operations: ₹1,492.50 (compared to ₹1,389.21 for H1 2025 and ₹1,730.55 for Q2 2026 [audited]).
Other Income: ₹0.00 (compared to ₹0.11 for Q2 2026 [audited]).
Total Income: ₹1,492.50.
Expenses: ₹1,260.99, including:
Purchases & Direct Expenses: ₹454.05.
Changes in Inventories: ₹22.79.
Employee Benefits Expense: ₹446.67.
Finance Costs: ₹27.92.
Depreciation & Amortization: ₹11.18.
Other Expenses: ₹298.38.
Profit Before Tax: ₹231.51 (compared to ₹185.09 for H1 2025 and ₹353.45 for Q2 2026 [audited]).
Tax Expense: ₹96.92 (₹61.64 current tax, ₹35.28 deferred tax).
Profit After Tax: ₹205.15 (compared to ₹141.96 for H1 2025 and ₹276.15 for Q2 2026 [audited]).
Earnings Per Share (Basic & Diluted): ₹2.31 (compared to ₹1.96 for H1 2025 and ₹4.00 for Q2 2026 [audited]).
Statement of Cash Flows (for half year ended 30th September 2026, in ₹ lacs)
Cash Flow from Operating Activities: ₹10.93, with cash generated from operations at ₹11.73 and income tax paid at ₹0.80.
Cash Flow from Investing Activities: -₹0.66, primarily from decrease in depreciation reserve.
Cash Flow from Financing Activities: ₹86.01, including:
Proceeds from long-term borrowings: ₹270.00.
Repayment of short-term borrowings: -₹79.66.
Proceeds from share capital: ₹891.00 (inferred from increase in share capital and reserves).
Finance cost paid: -₹27.92.
Share issue expenses: -₹21.68.
Net Increase in Cash and Cash Equivalents: ₹96.28.
Cash and Cash Equivalents at Beginning: ₹59.24 (as at March 31, 2026).
Cash and Cash Equivalents at End: ₹155.52.
Parties Involved
Board of Directors: Approved the financial results, with Amol Mujumdar (Managing Director) signing.
Audit Committee: Reviewed and recommended the financial results on 14th November 2026.
Statutory Auditors: B. Shroff & Co., Chartered Accountants (Firm Reg. No. 006514W), with CA Nilesh Tiwari (Partner) issuing the limited review report.
Compliance Officer: Ruchi Sanket Modi, Company Secretary, who signed the regulatory submissions.
Financial Impact
Explicitly quantified in the financial statements. No contingent exposures or unquantified impacts disclosed.
Capital Structure Impact
Share capital increased from ₹870.70 lacs to ₹1,140.70 lacs, indicating a share issuance during the period, with proceeds from share capital evident in cash flow.
Reserves and surplus increased significantly, contributing to higher equity.
Cash Flow Implications
Net cash inflow of ₹96.28 lacs, primarily from financing activities due to borrowings and share issuance, offset by operating and investing activities.
Guidance or Commentary
No forward-looking guidance or management commentary provided in the disclosure.
Notes to Financial Statements
The company is engaged only in the marketing and distribution of pharmaceutical products, so no segment reporting is required under AS 17.
The Code on Social Security, 2020, is not yet implemented, and its impact will be assessed upon notification.
Figures for previous periods have been re-grouped/re-arranged for comparability.
The financial results are available on the company's website at https://www.goldlinepharma.in/FinancialResults.html.
